During the past decade, Guido Moll has studied in collaboration with leading clinical stem cell and tissue engineering pioneers the immunomodulatory and
regenerative properties of human multipotent mesenchymal stromal cells (MSCs) and other advanced therapy medicinal products (ATMPs) in a highly translational
research environment at the Karolinska Institute in Stockholm, Sweden, the Berlin-Brandenburg Center/School for Regenerative Therapies (BCRT/BSRT) at the
Charité Universitätsmedizin Berlin, Germany, and the Queensland Institute for Medical Research (QIMR) in Brisbane, Australia. The goal of Guido’s research is to
enhance the safety and efficacy of novel ATMPs in various therapeutic approaches.